Toll Like Receptor 8 drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Oncology, Immunology, and Infectious Disease which include the indications Solid Tumor, Melanoma, Systemic Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus (SCLE), Hepatitis B, and Human Immunodeficiency Virus (HIV) Infections (AIDS). It also reviews key players involved in Toll Like Receptor 8 targeted therapeutics development with respective active and dormant or discontinued products.

The Toll Like Receptor 8 pipeline targets constitutes close to 40 molecules. Out of which, approximately 39 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 14, 12, 3, 16, and 3 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.

Toll Like Receptor 8 overview

Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.

For a complete picture of Toll Like Receptor 8’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.